








































Assessment of Efficacy of Proarrhythmia Biomarkers
in Isolated Rabbit Hearts With Attenuated
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Abstract: Isolated hearts with reduced repolarization reserve would
be suitable for assessing the proarrhythmic liability of drugs.
However, it is not known which proarrhythmia biomarkers indicate
the increased susceptibility to torsades de pointes arrhythmia (TdP)
in such experimental setting. Thus, we estimated the efficacy of
proarrhythmia biomarkers in isolated hearts with attenuated repolar-
ization reserve. Langendorff-perfused rabbit hearts were used.
Repolarization reserve was reduced by concomitant inhibition of
the rapid (IKr) and slow (IKs) delayed rectifier potassium currents by
dofetilide and HMR-1556, respectively. Rate corrected QT (QTc)
interval and beat-to-beat variability of the QT interval measured in
sinus rhythm or irrespective of rhythm even during arrhythmias
(sinus and absolute QT variability, respectively) were tested. QTc
failed to predict increased proarrhythmic risk. Sinus QT variability
indicated proarrhythmic liability when low concentration of dofeti-
lide was used. However, when arrhythmias compromised sinus var-
iability measurement during coperfusion of catecholamines and
elevated concentration of dofetilide, only absolute QT variability
indicated increased proarrhythmic risk. Absolute QT variability pa-
rameters seem to be the most practical and sensitive biomarkers of
proarrhythmic liability in rabbit hearts with reduced repolarization
reserve. Absolute QT variability parameters could serve as surro-
gates for torsades de pointes in drug-safety investigations in isolated
rabbit hearts with attenuated repolarization reserve.
Key Words: absolute beat-to-beat variability parameters, bio-
markers of proarrhythmia, Langendorff perfused rabbit heart, repo-
larization reserve, torsades de pointes
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INTRODUCTION
Drug-induced torsades de pointes (TdP) is a life-
threatening arrhythmia. Preclinical drug development requires
specific and sensitive surrogate biomarkers of TdP.1 To date,
still the electrocardiogram (ECG) QT and heart rate corrected
QT (QTc) intervals are the most accepted TdP surrogates by
the authorities.2,3 However, the predictive power of these
parameters has been questioned,4–7 therefore better predictors
of TdP are needed.
Temporal inhomogeneity of repolarization has been
reported to predict TdP development.6,8 Investigators prefer mea-
suring repolarization inhomogeneity in regular (arrhythmia-free)
rhythm because beat-to-beat variability of the repolarization in
regular rhythm predicted TdP in earlier investigations.9,10 How-
ever, the same variables measured in regular rhythm could not
forecast drug-induced TdP in other investigations.4,5,7,11 One of
the possible reasons for this controversy is that TdP is frequently
preceded by simple, drug-induced arrhythmias, which preclude
ECG interval measurement in regular rhythm. To overcome this
problem, we developed a method to allow ECG intervals to be
measured during disorganized nonsinus rhythm.5,12 This allowed
established beat-to-beat variability parameters to be derived irre-
spective of rhythm.5 To differentiate from published beat-to-beat
variability parameters derived during arrhythmia-free rhythm
(sinus beat-to-beat variability parameters), we coined the term
“absolute” to describe the beat-to-beat variability parameters
derived irrespective of rhythm.5 Absolute beat-to-beat variability
parameters of the ECG intervals accurately predicted drug-
induced TdP and ischemia-induced ventricular fibrillation
(VF), whereas equivalent variables measured in sinus rhythm
failed to predict TdP and VF liability.5,13
In human and in many mammals (eg, guinea pig, rabbit,
and dog), a considerable repolarizing current is the rapid
component of the delayed rectifier K+ current (IKr), which is
a common target of proarrhythmic drugs. However, under nor-
mal conditions, IKr block just rarely evokes TdP as other repo-
larizing currents, eg, the slow component of the delayed rectifier
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K+ current (IKs), become more prominent and decrease the ar-
rhythmogenic effect of the IKr blocker.
14,15 In contrast, the con-
comitant block of IKr and IKs currents reduces repolarization
reserve16 and constitutes an increased risk to TdP development.17
We hypothesized that isolated hearts with pharmaco-
logically reduced repolarization reserve would be suitable for
preclinical assessment of the proarrhythmic liability of drugs.
However, it is not known which proarrhythmia biomarker
indicates the increased proarrhythmic risk in such experi-
mental setting. Thus, the aim of our study was to investigate
which proarrhythmia biomarker (QTc, sinus or absolute beat-
to-beat variability of the QT interval) can adequately indicate
the increased proarrhythmic liability in the setting of reduced
repolarization reserve in an in vitro, spontaneously beating
rabbit heart proarrhythmia model. Reduced repolarization
reserve was achieved by concomitant pharmacological inhi-
bition of IKr and IKs.
METHODS
Animals
Female New Zealand white rabbits weighing 1.6–2.5
kg were used for the experiments. Animals were obtained
from WOBE Ltd (Budapest, Hungary) and acclimatized at
the site for at least 3–4 days before any experiments started.
Animals were kept under standard conditions (temperature
218C; relative humidity 55%–65%; 12:12-hour dark/light
cycle) on commercial laboratory chow and tap water ad libi-
tum. Animal maintenance and research were conducted in
accordance with the National Institutes of Health Guide for
the Care and Use of Laboratory Animals. All procedures
using animals were approved by the local ethics committee
(Ethical Committee for the Protection of Animals in Research
at the University of Szeged, Hungary) and conformed to the
rules and principles of the 86/609/EEC Directive.
General Methods
General experimental method was performed as
described earlier.18 The animals were anticoagulated with
sodium heparin (1000 IU) injected into the marginal ear vein
and stunned by a blow to the neck. The heart was rapidly
removed through thoracotomy and rinsed in ice-cold modified
Krebs–Henseleit buffer solution containing (in millimole):
NaCl 118.4, glucose 10.1, MgSO4 0.5, NaH2PO4 1.2, KCl
3, NaHCO3 25, and CaCl2 1.8. The aorta was cannulated and
hung on a Langendorff apparatus. The hearts were retro-
gradely perfused at a constant temperature of 378C with the
modified Krebs–Henseleit buffer solution described above. A
mixture of 95% O2 and 5% CO2 was bubbled through the
buffer, which was equilibrated to pH 7.4. All solutions were
filtered (5 mm pore size filter) before use. The perfusion pres-
sure was maintained constant at 80 mm Hg. Volume-
conducted ECG was recorded by using National Instruments
data acquisition hardware (PC card; National Instruments,
Austin, TX) and SPEL Advanced Haemosys software (ver-
sion 2.76; Experimetria Ltd and Logirex Software Labora-
tory, Budapest, Hungary). Coronary flow was measured
by timed collection of coronary effluent. Hearts were
equilibrated for 15 minutes before starting the experimental
protocol. At the end of each experiment, the atria were
removed from the heart and the ventricles were weighed.
Experimental Protocol
In the first set of experiments, 3 groups of hearts were
compared: (1) control group of hearts perfused with dimethyl
sulphoxide (DMSO), that is the solvent of dofetilide and
HMR-1556 (“Control A” group; n = 6), (2) hearts perfused
with dofetilide at 15 nM (“Dof 15” group; n = 8), and (3)
hearts perfused with HMR-1556 at 460 nM + dofetilide at 15
nM (“HMR + Dof 15” group; n = 6) (Table 1).
In the first set of experiments, there were only few drug-
induced arrhythmias; therefore, we performed a second set of
experiments, in which we intended to increase the incidence
of arrhythmias. In the second set of experiments, 4 groups
(each contained 8 hearts) were compared: (1) control group of
hearts perfused with DMSO and water, the latter is the solvent
of catecholamines (“Control B” group), (2) hearts perfused
with catecholamines (Cat) (adrenaline 25 nM + noradrenaline
100 nM) + DMSO (“Cat Control” group), (3) hearts perfused
with catecholamines + dofetilide at 50 nM (“Cat + Dof 50”
group), and (4) hearts perfused with catecholamines + HMR-
1556 at 460 nM + dofetilide at 50 nM (“Cat + HMR + Dof
50” group) (Table 2).
The administration of the IKs inhibitor HMR-1556 or its
solvent (DMSO) was started at the beginning of a 30-minute
pretreatment period. Dofetilide or its solvent (DMSO) was added
to the perfusion solution after the pretreatment period, at the
beginning of a 30-minute treatment period. In the second set of
experiments, catecholamines or their solvent were administered
from the beginning of the pretreatment period (Tables 1 and 2).
In the first set of experiments, we aimed to achieve
a sufficient impairment of the repolarization without pro-
voking a prominent arrhythmic activity. Thus, the selective
IKr blocker dofetilide was applied at a concentration of
15 nM, which inhibited approximately 50% of the IKr K+
current19,20 and led to QTc prolongation without significant
arrhythmic activity in our pilot study.
In the second set of experiments, we intended to increase
the incidence of arrhythmias by further repolarization impair-
ment. The concentration of dofetilide was increased to 50 nM
to achieve complete inhibition of IKr. Because IKs blockade did
not significantly increase repolarization instability unless
b-adrenergic stimulation was added in canines in vivo,21,22 cat-
echolamines were added to the perfusion solution to mimic the







Control A (n = 6) Vehicle Vehicle
Dof 15 (n = 8) Vehicle Dofetilide 15 nM
HMR + Dof 15 (n = 6) HMR HMR + Dofetilide 15 nM
“Dof 15”, group perfused with 15 nM dofetilide; “HMR + Dof 15”, group perfused
with 460 nM HMR-1556 and 15 nM dofetilide; HMR, HMR-1556 at 460 nM; vehicle,
DMSO (dimethyl sulphoxide), the common solvent of the dofetilide and HMR-1556.
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sympathetic activity and to boost the function of IKs (and the
effect of IKs inhibition) in the isolated rabbit hearts.
Because the IKs inhibitor HMR-1556 may adsorb to glass
or plastic surfaces, leading to reduced effective drug concen-
trations in the heart, the concentration of HMR-1556 was mea-
sured in the perfusate right above the heart by the means of
spectrophotometry (Hitachi F-4000; Hitachi Ltd, Tokyo, Japan)
with an excitation and emission wavelength of 295 and 325 nm,
respectively (data not shown). Because the IC50 of HMR-1556
ranged between 10.523 and 65 nM,17 our target concentration of
HMR-1556 was 250 nM to achieve a significant inhibition of
the IKs. However, it was found in the pilot experiments that the
concentration of HMR-1556 in the perfusate was lower at the
level of the aorta than in the working buffer. Thus, we increased
the concentration of HMR-1556 to 460 nM in the working
buffer, which resulted in a stable concentration of approxi-
mately 250 nM HMR-1556 in the perfusate at the level of the
hearts in our perfusion setup.
Experiments were randomized, and blinded analysis was
achieved by using stock solutions prepared by a second operator,
who did not participate in the experimental work or data analysis.
Drugs and Materials
Perfusion solutions were prepared fresh each day.
Dofetilide and HMR-1556 were synthesized at Gedeon
Richter Plc (Budapest, Hungary) and were dissolved in
DMSO. All final test solutions for heart perfusion contained
0.045 mL DMSO in 1 L of modified Krebs–Henseleit solu-
tion. Catecholamines (adrenaline and noradrenaline) were
purchased from Sigma Aldrich, Inc (St. Louis, MO) and were
dissolved in water acidified with ascorbic acid; all final test
solutions for heart perfusion contained 0.2 mL water and 25
mmole ascorbic acid in 1 L of modified Krebs–Henseleit
solution in the second set of experiments.
Chemicals for modified Krebs–Henseleit physiological
solution were purchased from Reanal Private Ltd (Budapest,
Hungary). DMSO and ascorbic acid were obtained from
Sigma–Aldrich, Inc. Water for the preparation of perfusion solu-
tion was obtained from a reverse osmosis system (Milli-Q RG;
Millipore Ltd, Billerica, MA) fed by distilled water and had
a specific resistivity of .18 MV.
Exclusion Criteria
Any heart with a sinus rate ,120/min or a coronary
flow .10 mL$min21$g21 or ,3 mL$min21$g21 5 minutes
before the start of the 60-minute drug perfusion protocol or
not in a constant sinus rhythm before the start of the 60-
minute drug perfusion, was excluded. The excluded hearts
were replaced to maintain equal group sizes when they may
influence the main result.
Arrhythmia Diagnosis
The incidence and the time to onset of arrhythmias were
determined. Ventricular premature beat (VPB), bigeminy,
salvo, ventricular tachycardia (VT), and VF were defined
according to the Lambeth Conventions.24 TdP was defined as
a polymorphic VT consisting of 4 or more ventricular com-
plexes where clear twisting of the QRS complexes around the
isoelectric axis could be seen in at least 1 ECG lead.12 Runs of
4 or more VPBs without the TdP-like twisting QRS morphol-
ogy were differentiated from TdP and were defined as VT.
Blocks in the conduction system were also monitored because
blocks frequently occur in rabbits treated with repolarization
prolonging drugs.25 Conduction disturbances included atrio-
ventricular blocks and intraventricular conduction defects
(right or left bundle branch blocks).5
Measurement of the ECG Intervals and QTc
ECG intervals were measured in sinus rhythm at
predetermined time points (14, 25, 35, 44, 50, and 55 minutes).
After the completion of experiments, the data were replayed
with the SPEL Advanced Haemosys software (version 2.76;
Experimetria Ltd and Logirex Software Laboratory). The
software averaged the ECG signal from 20 consecutive sinus
beats at the predetermined time point. If there were not 20
consecutive sinus beats at the predetermined time point or in
the preceding or subsequent 30 seconds, then the measurement
was not performed at the time point. The RR and QT intervals
were measured by manual positioning on screen markers in the
signal-averaged ECG. Heart rate was calculated from the RR
interval. The QT interval was defined as the time from the first
deviation from the isoelectric line during the PR interval until
the end of the T wave. Where the T wave overlapped the
following P wave or the QRS complex of the subsequent beat,
the extrapolation method was used to measure the length of the
QT interval, that is, the end of the T wave was extrapolated
from the curve of the T wave to the isoelectric line under the P
wave or the QRS complex.25
The QT interval is influenced by the heart rate, thus
rate-corrected QT interval (QTc) was calculated with a cor-
rection method described earlier.26,27 Baseline data in sinus
rhythm for QT intervals together with the corresponding RR
intervals were obtained from pooled data of our laboratory
(from 100 isolated, Langendorff-perfused rabbit hearts pre-
pared as described above). The linear regression between the
QT interval and the preceding RR interval was: QTn + 1 =
0.34 RRn + 90 (Fig. 1A). This equation was rearranged to
allow the calculation of the rate-corrected QT interval at
a mean RR interval of 340 milliseconds (ie, a ventricular rate
of approximately 177 beats per minute) using the formula








Control B (n = 8) Vehicles Vehicles
Cat control (n = 8) Cat. + vehicle Cat. + vehicle
Cat + Dof 50 (n = 8) Cat. + vehicle Cat. + Dofetilide 50 nM
Cat + HMR + Dof 50
(n = 8)
Cat. + HMR Cat. + HMR + Dofetilide 50 nM
Vehicles in the “Control B” group are water acidified with ascorbic acid (the solvent
of the catecholamines) and DMSO (the common solvent of the dofetilide and HMR-
1556). Vehicle in the other groups is only DMSO. For further details see Table 1.
“Cat + Dof 50”, group perfused with catecholamines and 50 nM dofetilide; “Cat +
HMR + Dof 50”, group perfused with catecholamines, 460 nM HMR-1556 and 50 nM
dofetilide; Cat., catecholamines (adrenaline 25 nM + noradrenaline 100 nM).
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QTcn + 1 = QTn + 1 2 0.34 (RRn 2 340). With these equa-
tions, plotting QTc against the corresponding RR interval
produces a regression line with a slope of zero (Fig. 1B),
indicating that these corrections successfully removed the
influence of heart rate.
Measurement of the Absolute and Sinus Beat-
to-beat Variability of the QT and RR Interval
To determine beat-to-beat variability of the RR and QT
intervals, all analyses were based on samples of 40 consec-
utive ventricular complexes (RR intervals) at the predeter-
mined time points, that is at baseline (1 minute before the
pretreatment period), in the last minute of the pretreatment
period, and in the fifth minute of the treatment period. From
these samples, each of the 40 RR and QT intervals was
measured manually, then the short-term variability (STV) and
the long-term variability (LTV) of the RR and QT intervals
were derived as follows.
Short-term Variability
In terms of a Poincaré plot, which is a plot of the value of
an ECG interval (di + 1) against the preceding value (di), one
can visualize the STV as the mean perpendicular distance
between the points of the plot and the diþ1 ¼ di line. This
corresponds to the following formula as described by Thomsen







ðdiþ12diÞ, where di represents the
sequence of the ECG interval durations and N is the total
number of intervals.
Long-term Variability
In the framework outlined above, LTV is the mean
distance (measured parallel to the diþ1 ¼ di line in the Poin-
caré plot) between the individual interval durations (di) and









The derived beat-to-beat variability parameters
described above are referred to absolute beat-to-beat variabil-
ity parameters when the raw ECG interval data were taken
irrespective of the rhythm ie, regardless of whether rhythm
was sinus or nonsinus at the time point of the measurement.
The derived beat-to-beat variability parameters described
above are referred to sinus beat-to-beat variability parameters
when the raw ECG interval data were taken from samples of
40 consecutive complexes strictly in sinus rhythm at the
predetermined time point. The sample of 40 consecutive sinus
complexes was measured only if it was preceded by at least
10 arrhythmia-free beats to avoid any effect of preceding
arrhythmias on the ECG intervals.
In the first set of experiments, arrhythmias were infrequent
at the predetermined time points; therefore the measurement of
the ECG intervals could be done in stable sinus rhythm. Thus,
only sinus beat-to-beat variability parameters were determined at
all of the predetermined time points. However, in the second set
of experiments, hearts usually experienced arrhythmias during
drug perfusion at the predetermined time points. Thus, the
measurement of the ECG intervals in sinus rhythm must have
been done before the predetermined time point; if there were not
50 consecutive sinus beats at the predetermined time point or in
the preceding 2 minutes, then the measurement was not
performed, and sinus beat-to-beat variability parameters were
not determined at the time point.
The percent frequency of arrhythmic beats (defined as
VPBs or individual QRT complexes in a run of a salvo or VT)
was calculated as number per 40 beats 100 times in each
sample used for measuring absolute beat-to-beat variability of
the ECG intervals in the second set of the experiments.
Statistics
Continuous data were expressed as mean 6 SEM. All
data from independent samples, except arrhythmia incidences,
were compared with Kruskal–Wallis tests. The incidences of
FIGURE 1. A, Correlation between individual values of the
QTn+1 interval and the preceding RR (RRn) interval in sinus
rhythm in isolated Langendorff-perfused rabbit hearts. B,
Correlation between individual values of the “rate corrected”
QTn+1 (QTcn+1) interval and the preceding RR (RRn) interval in
sinus rhythm in isolated Langendorff-perfused rabbit hearts.
QTc was calculated using the formula QTcn + 1 = QTn + 1 2
0.34 (RRn 2 340). All panels contain 3900 baseline data points
obtained from 100 isolated rabbit hearts.
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arrhythmias were compared by using Fisher’s exact probability
test with the Bonferroni correction, ie, the P values of Fisher’s
exact probability test were multiplied by the number of com-
parisons between the groups to allow multiple comparisons.28
P , 0.05 was taken as indicative of a statistically significant
difference between values.
RESULTS
Arrhythmia Incidences, Frequency, and Onset
Time of Arrhythmias
First Set of Experiments
Hearts were in sinus rhythm during the “pretreatment”
period; HMR-1556 (without dofetilide) did not evoke ar-
rhythmias. Dofetilide tended to increase arrhythmia inciden-
ces in the Dof 15 and HMR + Dof 15 groups in the
“treatment” period, but there were no significant differences
in the arrhythmia incidences among the groups (data not
shown). Dofetilide induced TdP in 1 heart (13%) in the Dof
15 group; the drug did not evoke VF. There were no signif-
icant differences in the onset times of arrhythmias between
the groups (data not shown).
Second Set of Experiments
As expected, catecholamines increased arrhythmic
activity (Fig. 2). In the pretreatment period, catecholamine
perfusion evoked mostly VPBs, the incidences of other types
of arrhythmias (bigeminy, salvo, and VT) were low. HMR-
1556 on top of catecholamines did not increase the incidence
of any arrhythmias; there were no significant differences in
the incidences of arrhythmias between the groups (data not
shown). TdP and VF did not occur in this period.
In the treatment period, addition of dofetilide on top of
HMR-1556 and catecholamines significantly increased the
frequency of arrhythmic beats as compared with control
(Figs. 2, 3). However, there were no significant differences in
the incidences of VPB, BG, and salvo among the groups (data
not shown). TdP did not occur in the control groups, but
dofetilide induced TdP in 1 heart in both dofetilide-perfused
groups. Dofetilide coperfused with HMR-1556 and catechol-
amines tended to increase VT and VF incidences, but there
were no significant differences in the incidences of VT and
VF among the groups (VT: 0%, 25%, 38%, and 63%; VF:
0%, 0%, 25%, and 38% in the Control B, Cat control, Cat +
Dof 50, and Cat + HMR + Dof 50 groups, respectively).
Coperfusion of dofetilide, HMR-1556, and catecholamines
significantly increased the incidence of conduction blocks
as an indirect sign of markedly prolonged repolarization
[block incidences: 0%, 0%, 50%, and 75% (P , 0.05 vs.
Control B and Cat control) in Control B, Cat control, Cat +
Dof 50, and Cat + HMR + Dof 50 groups, respectively].
There were no significant differences in the onset times of
arrhythmias between the groups (data not shown).
QTc Interval and Heart Rate in Sinus Rhythm
First Set of Experiments
QTc did not differ between the groups in the pre-
treatment period (data not shown). In the treatment period,
administration of dofetilide for 10 minutes significantly
prolonged the QTc interval; however, QTc did not differen-
tiate between the Dof 15 and the HMR + Dof 15 groups
(Fig. 4A). Occurrence of dofetilide-induced arrhythmias did
not allow measurement of the QTc interval after 10 minutes
of dofetilide perfusion. There was no significant difference in
the heart rate between the groups during the whole experi-
ment (Fig. 5A).
Second Set of Experiments
QTc did not differ between the groups at baseline and in
the pretreatment period, before dofetilide perfusion (data not
shown). In the treatment period, administration of dofetilide
for 10 minutes significantly widened the QTc interval;
however, QTc did not differentiate between the Cat + Dof
50 and the Cat + HMR + Dof 50 groups (Fig. 4B); dofetilide-
induced arrhythmias prevented further measurements of the
biomarker at the subsequent time points. Although catechol-
amines increased heart rate (Figs. 3, 5B), and HMR-1556
tended to cause bradycardia, there was no significant differ-
ence in the heart rate between the groups during the whole
experiment (Fig. 5B).
Temporal Inhomogeneity of the
Repolarization and the Cycle Length
First Set of Experiments
The STV and LTV parameters of the RR and QT
intervals were determined in sinus rhythm (sinus variability
parameters). The sinus STV QT and the sinus LTV QT
parameters did not differ between the groups at baseline and
during the pretreatment period (data not shown). In the
treatment period, dofetilide perfusion for 5 minutes increased
the sinus STV QT and the sinus LTV QT values. Importantly,
both sinus STV QT and sinus LTV QT increased significantly
in the HMR + Dof 15 group as compared with the values in
the Dof 15 and the Control A groups (Fig. 6). The sinus
variability parameters could not be determined at subsequent
FIGURE 2. Percent frequency of arrhythmic beats in 40 con-
secutive ventricular beats at baseline (baseline), in the
last minute of the pretreatment period (pretreatment), and
5 minutes after the start of the dofetilide (or its vehicle) per-
fusion (treatment) in the second set of experiments. *P , 0.05
versus Control B group. For further details, see Table 2.
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time points because of frequent occurrence of dofetilide-
induced arrhythmias. There was no significant difference in
any of the variability parameters of the RR interval at any
time points between the groups (data not shown).
Second Set of Experiments
The STV and LTV of the RR and QT intervals were
determined not only in sinus rhythm (sinus variability
parameters) but also irrespective of the rhythm (absolute
variability parameters).
The Sinus Variability Parameters of the ECG
Intervals
The sinus variability parameters of the QT and RR
intervals did not differ significantly between the groups at any
predetermined time points (Figs. 7, 8). Neither catechol-
amines nor HMR-1556 influenced the sinus variability pa-
rameters during the pretreatment period (data not shown).
Dofetilide coadministered with HMR-1556 for 5 minutes
increased the sinus STV QT and LTV QT in the Cat +
HMR + Dof 50 group as compared with the values of the
Cat + Dof 50 and the control groups. However, the effect was
not significant, most probably because the parameter could be
determined only in 5 hearts in the Cat + HMR + Dof 50 group
because of frequent occurrence of dofetilide-induced arrhyth-
mias (Fig. 7). These arrhythmias did not allow measurement
of the sinus variability parameters at subsequent time points.
The Absolute Beat-to-beat Variability of the
ECG Intervals
Unlike sinus variability parameters, absolute variability
parameters could be determined in all hearts because
measurement of the absolute variability parameters is not
restricted to sinus rhythm. None of the absolute variability
parameters of the RR and QT intervals differed between the
groups at baseline and during the pretreatment period (data
not shown). In the treatment period, coperfusion of dofetilide
with HMR-1556 for 5 minutes increased the absolute
variability parameters of the QT and RR intervals (Figs. 7–9).
Importantly, the absolute STV QT and the absolute LTV QT
parameters differentiated between the Cat + Dof 50 and Cat +
HMR + Dof 50 groups; that is, the absolute variability param-
eters of the QT interval were significantly increased in the Cat +
HMR + Dof 50 group as compared with the values in the Cat +
Dof 50 group (Fig. 7).
Coronary Flow
The mean baseline coronary flow values ranged from
4.1 6 0.3 to 7.3 6 0.5 mL$min21$g21 in the first set of
experiments and from 4.2 6 0.3 to 7.4 6 0.7 mL$min21$g21
in the second set of experiments. There was a small time-
dependent fall in the coronary flow values during the experi-
ments in all groups. In the first set of experiments, there was no
significant difference in the coronary flow between the groups.
In the second set of experiments, catecholamine perfusion
FIGURE 3. An example of development of dofetilide-induced arrhythmias when coperfused with HMR-1556 and catecholamines
in a heart from the second set of experiments. ECG signals were recorded before drug administration (baseline), in the last minute
of the pretreatment period (pretreatment), and 2 and 5 minutes after starting dofetilide perfusion (treatment 2 and treatment
5 minutes, respectively). S, sinus beat; VPB, ventricular premature beat; VT, ventricular tachycardia.
FIGURE 4. The QTc intervals 10 mi-
nutes after the start of the dofetilide
(or its vehicle) perfusion in the first
set of experiments (A) and in the
second set of experiments (B). †P ,
0.05 versus Control A group;
*P , 0.05 versus Control B group;
#P , 0.05 versus Cat control
group. For further details, see Tables
1 and 2.
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increased the flow slightly but there was no significant differ-
ence in the coronary flow between the groups (data not shown).
DISCUSSION
QTc failed to predict the known increased risk of
proarrhythmia in the setting of reduced repolarization reserve.
However, a significant elevation in the sinus beat-to-beat
variability values of the QT interval (sinus STV QT and LTV
QT) indicated the increased probability of proarrhythmia,
when drug-induced arrhythmias were infrequent during
administration of a low concentration of dofetilide. In
contrast, when catecholamines and an elevated concentration
of dofetilide was applied, sinus beat-to-beat variability
parameters of the QT interval could not forecast an increased
hazard to proarrhythmia occurrence because frequent drug-
induced arrhythmias precluded measurement of the beat-to-
beat variability parameters in sinus rhythm. However,
increased absolute beat-to-beat variability parameters of the
QT interval (absolute STV QT and LTV QT), which are
determined irrespective of the rhythm even during arrhyth-
mias, were indicatives of the increased proarrhythmic liability
in the setting of reduced repolarization reserve even when
frequent arrhythmias compromised the measurement of the
sinus STV QT and LTV QT.
Decreased Repolarization Reserve Augments
Risk of Proarrhythmia and Limits the Use of
Biomarkers Restricted to Sinus Rhythm
Based on the theory of repolarization reserve,
the fine-tuned function of repolarization currents may
compensate the lack of a repolarizing current,16 eg, IKs
may compensate the decreased function of IKr. However,
a multiple hit on repolarization might lead to an excessive
prolongation of the action potential duration (APD) and
may render the cardiac muscle more susceptible to
proarrhythmia.9,29
Reduction of repolarization reserve increased the
incidence of dofetilide-induced TdP in dogs and rabbits
in vivo.9 Also, it was documented that the increased beta-
adrenergic tone augmented the effect of the IKs inhibitor
HMR-1556 on refractoriness observed at rapid rates in can-
ines in vivo.21 Interestingly, neither increased concentration
of dofetilide nor boosted HMR-1556-induced IKs inhibition
due to catecholamine administration could initiate signifi-
cant amount of dofetilide-induced TdP in the present inves-
tigation in isolated rabbit hearts, which highlights the
importance of the surrogate biomarkers of TdP in preclinical
drug-safety investigations. The exact reason why a low inci-
dence of TdP was observed in the present investigation is
not examined. The incidence of TdP might have been
increased with the application of higher concentrations of
dofetilide and HMR-1556 (unpublished results from our lab-
oratory); however, this was not the primary aim of this
study. The combined IKs and IKr blockade did increase the
frequency of less complex arrhythmias, and thus, prevented
the use of proarrhythmia biomarkers that are based on ECG
interval measurement restricted to sinus rhythm. However,
the occurrence of arrhythmias provided scope for testing the
predictive power of the novel proarrhythmia biomarkers, the
absolute variability parameters5 that are not restricted to
sinus rhythm.
FIGURE 5. The heart rate in the first
set of experiments (A) and in the
second set of experiments (B). HMR-
1556 (or its vehicle) perfusion
commenced at 0 minute (pre-
treatment period). Catecholamine
perfusion was applied only in the
second set of experiments; cate-
cholamine (or vehicle) perfusion
commenced at 0 minute (pre-
treatment period). Dofetilide (or its
vehicle) perfusion began at 30 mi-
nutes (treatment period). For fur-
ther details, see Tables 1 and 2.
FIGURE 6. The STV and the LTV of
the QT interval 5 minutes after the
start of the dofetilide (or its vehicle)
perfusion in the first set of experi-
ments. *P , 0.05 versus Control
A group; †P , 0.05 versus Dof
15 group. For further details, see
Table 1.
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QTc Failed to Predict Increased
Proarrhythmia Risk in Reduced Repolarization
Reserve
In this study, the IKr blocker dofetilide caused a signif-
icant QTc interval prolongation. However, the IKs inhibitor
HMR-1556 did not lengthen the QTc interval. Similarly, IKs
inhibition did not prolong the QTc interval in isolated rabbit
hearts14 and did not lengthen the APD in cardiac papillary
muscles14 reinforcing that IKs may have little role in normal
action potential repolarization and it probably plays a vital
role when cardiac APD is abnormally lengthened by other
means.29 Dofetilide alone and coperfused with the IKs blocker
HMR-1556 caused an equivalent degree of QTc prolongation,
thus the extent of the QTc prolongation did not differ between
the presence and absence of the IKs inhibition. Similarly,
Lengyel et al9 found that the concomitant inhibition of IKs
and IKr with dofetilide and HMR-1556 did not prolong the
QTc interval significantly as compared with that achieved by
the IKr inhibition in anaesthetized rabbits and dogs in vivo.
These results emphasize that QTc interval is not a suitable
biomarker to identify increased proarrhythmia liability in case
of attenuated repolarization reserve.
FIGURE 7. The sinus and absolute
STV and LTV parameters of the QT
interval in the treatment period,
5 minutes after the start of the do-
fetilide (or its vehicle) perfusion
in the second set of experiments.
*P , 0.05 versus Control B group;
#P , 0.05 versus Cat control group;
†P , 0.05 versus Cat + Dof
50 group. For further details, see
Table 2.
FIGURE 8. The sinus and absolute
STV and LTV parameters of the RR
interval in the treatment period,
5 minutes after the start of the do-
fetilide (or its vehicle) perfusion in
the second set of experiments. *P ,
0.05 versus Control B group; #P ,
0.05 versus Cat control group;
†P , 0.05 versus Cat + Dof 50
group. For further details, see
Table 2.
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Sinus Beat-to-beat Variability of the
Repolarization is a Better Predictor of
Proarrhythmia in Reduced Repolarization
Reserve, but Arrhythmic Activity Limits Its Use
It has been suggested that temporal dispersion of
repolarization could predict proarrhythmic events.30,31 It was
found in the chronic atrioventricular node-blocked dog model
that a downregulation of several potassium currents, most
notably the IKs channel, occurs because of the electrical re-
modeling.32 Additional pharmacological block of IKr did not
prolong the QTc interval significantly in the dog model, but
increased the beat-to-beat variability of the repolarization
(STV QT), when it was measured in arrhythmia-free, regular
rhythm.8 Lengyel et al9 measured STV QT in sinus rhythm in
rabbits in vivo and directly demonstrated that TdP evoked by
combined pharmacological block of IKr and IKs can be better
predicted by increased STV QT than by QTc changes alone.
Carlsson et al10 reported that dofetilide increased STV QT in
sinus rhythm before the occurrence of VPBs and TdP in
methoxamine-sensitized, anaesthetized rabbits. However,
sinus STV QT did not predict TdP in other studies using
a similar, anaesthetized rabbit model.4,5,7
In the first set of experiments in this investigation, the
measurement of the beat-to-beat variability of the QT
intervals was possible in sinus rhythm at the predetermined
time points because the arrhythmic activity was low during
concomitant pharmacological inhibition of IKs and IKr. In the
group perfused with dofetilide together with HMR-1556, the
beat-to-beat variability parameters of the QT interval were
significantly increased as compared with those in the control
group, and more importantly, compared with those in the
group perfused only with dofetilide. Accordingly, STV QT
and LTV QT could differentiate the combined ion-channel
block from the sole IKr block identifying the increased proar-
rhythmia liability during decreased repolarization reserve.
However, in the second set of experiments, catechol-
amines and elevated concentration of dofetilide increased the
arrhythmic activity, which precluded the measurement of the
sinus beat-to-beat variability parameters of the QT intervals,
thus these parameters failed to indicate the increased proar-
rhythmic liability of the drugs during reduced repolarization
reserve. These results show that sinus beat-to-beat variability
parameters of the repolarization (sinus STV QT and LTV QT)
are better predictors of proarrhythmic liability than QTc in
reduced repolarization reserve, but the application of these
parameters is limited when arrhythmia occurs.
Absolute Beat-to-beat Variability of the
Repolarization Is the Best Proarrhythmia
Predictor in Reduced Repolarization Reserve
Dofetilide was used as a reference drug because it can
cause TdP in humans and animal models.5,7–9,12,33 Earlier
FIGURE 9. Poincaré plots of the QT and RR intervals measured irrespective of the rhythm in 1 representative experiment from
Control B group (A and E), in 1 representative experiment from Cat control group (B and F), in 1 representative experiment from
Cat + Dof 50 group (C and G), and in 1 representative experiment from Cat + HMR + Dof 50 group (D and H). Values were
measured at baseline (baseline), in the last minute of the pretreatment period (pretreatment) and 5 minutes after the start of the
dofetilide (or its vehicle) perfusion (treatment) in the second set of experiments. For further details, see Table 2.
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investigations showed that increased temporal variability of
repolarization provides increased risk for development of
drug-induced TdP.5,8 Dofetilide-induced temporal variability
of repolarization measured by absolute STV QT and LTV QT
increased markedly when the drug was coadministered with
HMR-1556 and catecholamines in this investigation. This
indicates that reduced repolarization reserve achieved by
pharmacological inhibition of IKs helps to reveal the proar-
rhythmic liability of IKr inhibitors in isolated rabbit hearts.
In the presence of reduced repolarization reserve,
ectopic beats can render the APD unstable for many beats6
and thus produce large beat-to-beat irregularity.34 Moreover,
increased variability of repolarization may remain latent until
the heart is disturbed by an ectopic beat.35 In a previous in-
vivo study, most TdP events were preceded by noncomplex
arrhythmias (eg, VPBs and salvos) in anesthetized rabbits.5
Similar noncomplex arrhythmias occurred frequently in the
second set of experiments in the present in vitro investigation,
when hearts were sensitized to arrhythmia development by
the coperfusion of catecholamines and an elevated concentra-
tion of dofetilide. Because TdP rarely occurs spontaneously
without preceding arrhythmias, however, the number of
arrhythmic beats was not a precise predictor of drug-
induced TdP,5 new TdP biomarkers that can be measured
irrespective of rhythm even during arrhythmias are needed.
The predictive power of the sinus beat-to-beat variability of
the repolarization is not consistent especially when frequent
arrhythmias preclude its measurement. However, the newly
developed absolute beat-to-beat variability parameters of the
ECG intervals seem to be more reliable surrogate biomarkers
of TdP.5 Indeed, in this study, where the sinus beat-to-beat
variability was not predictive in the second set of experi-
ments, the absolute beat-to-beat variability parameters of the
repolarization still indicated the increased proarrhythmic lia-
bility of dofetilide in the setting of decreased repolarization
reserve.
CONCLUSIONS
QTc prolongation did not identify the increased proar-
rhythmic risk of dofetilide in the setting of reduced repolar-
ization reserve. In contrast, the sinus beat-to-beat variability
of QT interval was a sensitive biomarker for proarrhythmia in
the setting of decreased repolarization reserve. However,
when measurement of the sinus variability parameters was
compromised by arrhythmias, only absolute beat-to-beat
variability parameters of the repolarization could reveal the
increased proarrhythmic liability. Thus, absolute QT variabil-
ity parameters seem to be the most practical and sensitive
biomarkers of proarrhythmic liability in the setting of reduced
repolarization reserve. Absolute STV QT and LTV QT could
serve as surrogates for TdP in drug-safety investigations in
isolated rabbit hearts with attenuated repolarization reserve.
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